Want to see CH:SFZN full AI Analyst Report?
Siegfried Holding AG (SFZN) AI Stock Analysis
Siegfried Holding AG
(Six Swiss:SFZN)
The score is driven primarily by solid profitability and a generally sound balance sheet, supported by a constructive technical trend. It is held back by weak/volatile free cash flow and a valuation that is only moderate given the low dividend yield; the latest earnings call adds modest support via reaffirmed guidance but flags near-term cash flow and leverage pressures post-acquisition.
Siegfried Holding AG (SFZN) vs. iShares MSCI Switzerland ETF (EWL)
- Market Cap
- CHF 3.86B
- Dividend Yield
- 0.56%
- Average Volume (3M)
- 110.39K
- Price to Earnings (P/E)
- 18.4
- Beta (1Y)
- 0.87
- Revenue Growth
- 3.64%
- EPS Growth
- 10.93%
- Country
- Switzerland
- Employees
- 4,454
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Siegfried Holding AG Business Overview & Revenue Model
Company Description
Siegfried Holding AG, together with its subsidiaries, engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide. It offers drug substances, including exclusive synthesis that manuf...
How the Company Makes Money
Siegfried makes money primarily by providing contract services to pharmaceutical and biotech companies and charging for development work and manufacturing output. Its revenue model is centered on (1) Drug substance (API) business: fees and manufactur...
Siegfried Holding AG Earnings Call Summary
The call balanced clear operational and strategic progress (top-line growth, margin expansion, strong commercial traction, successful technology and site milestones, acquisition integration on track) against near-term financial impacts from the acquisition (lower operating cash flow, higher inventory and leverage, and FX headwinds). Management reconfirmed guidance and emphasized focus on cash generation and deleveraging, with multiple execution milestones supporting the strategic outlook.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management reconfirmed full‑year 2026 guidance of high single‑digit revenue growth in local currencies and a core EBITDA margin above 23%. In H1 they reported net sales of CHF 633m (+2.2% reported, +4.8% L.C.), with Drug Substances CHF 431.1m (68.1% of sales) and Drug Products CHF 201.9m; core EBITDA margin rose to 22.4% from 21.6% (an 80 bps improvement) and core gross profit was CHF 170.7m (+4.7% YoY). Cash and balance‑sheet metrics: operating cash flow CHF 93.7m (vs CHF 149.6m prior), free cash flow CHF 15.1m, acquisition cash outflows CHF 157.4m, financing inflows CHF 143.3m, and net debt to core EBITDA of 2.3x; the acquisition is expected to contribute roughly USD 100m on an annualized basis, USD exposure rose to 14% in H1 (forecast ~20% for FY) and management assumes an approximately 2% FX headwind for the year. Capital allocation and execution priorities were reiterated: CapEx targeted in the low‑teens of sales (moving closer to 10%), focus on cash generation and deleveraging, and operational milestones include freeing 80 m3 of U.S. capacity (available from 2028) with first transfers this year and first revenues from new U.S. business expected in 2027.
Siegfried Holding AG Financial Statement Overview
Summary
Strong profitability and steady revenue growth support the score, and leverage has generally improved over time. The main offset is weak and volatile free cash flow (thin in 2025 and negative in some recent years), indicating poor cash conversion despite solid earnings.
Income Statement
78PositiveBalance Sheet
74PositiveCash Flow
52Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.34B | 1.33B | 1.29B | 1.27B | 1.23B | 1.10B |
| Gross Profit | 361.70M | 352.39M | 329.06M | 320.41M | 318.69M | 239.27M |
| EBITDA | 313.22M | 306.70M | 289.49M | 241.22M | 308.30M | 213.54M |
| Net Income | 171.34M | 168.66M | 160.06M | 112.77M | 156.49M | 95.60M |
Balance Sheet | ||||||
| Total Assets | 2.42B | 2.15B | 1.93B | 1.86B | 1.79B | 1.67B |
| Cash, Cash Equivalents and Short-Term Investments | 105.16M | 103.80M | 39.61M | 56.63M | 91.62M | 72.97M |
| Total Debt | 925.20M | 575.20M | 490.10M | 525.00M | 590.00M | 560.00M |
| Total Liabilities | 1.42B | 1.03B | 953.81M | 1.02B | 1.08B | 1.06B |
| Stockholders Equity | 994.68M | 1.13B | 980.19M | 838.24M | 710.93M | 608.22M |
Cash Flow | ||||||
| Free Cash Flow | -18.24M | 9.97M | -12.07M | 71.51M | 19.30M | -1.04M |
| Operating Cash Flow | 165.84M | 221.89M | 168.78M | 208.61M | 134.50M | 112.36M |
| Investing Cash Flow | -358.07M | -231.31M | -190.35M | -146.86M | -103.72M | -250.10M |
| Financing Cash Flow | 262.33M | 74.83M | 3.04M | -94.75M | -10.68M | 156.24M |
Siegfried Holding AG Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:SFZN, the sentiment is Negative. The current price of 71.80 is above the 20-day moving average (MA) of 70.71, below the 50-day MA of 71.81, and below the 200-day MA of 77.33, indicating a neutral trend. The MACD of 0.23 indicates Negative momentum. The RSI at 50.45 is Neutral, neither overbought nor oversold. The STOCH value of 28.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:SFZN.
Siegfried Holding AG Peers Comparison
Overall Rating
CH:GALD80Outperform
CH:ALC73Outperform
CH:TECN68Neutral
CH:SDZ67Neutral- CH:SFZN66.8Neutral
CH:PPGN53Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| CH:GALD | 80Outperform | CHF 44.97B | 63.88 | ― | 0.18% | 15.78% | 111.61% |
| CH:ALC | 73Outperform | CHF 29.53B | 54.96 | 2.91% | 0.47% | -0.87% | -44.90% |
| CH:TECN | 68Neutral | CHF 3.17B | -26.96 | -10.25% | 1.21% | -3.98% | -284.91% |
| CH:SDZ | 67Neutral | CHF 36.25B | 67.02 | 7.04% | 0.97% | 0.81% | 165.32% |
| CH:SFZN | 67Neutral | CHF 3.24B | 18.36 | 16.14% | 0.56% | 3.64% | 10.93% |
| CH:PPGN | 53Neutral | CHF 1.39B | 105.85 | ― | ― | 22.06% | ― |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CH:SFZN | Siegfried Holding AG | 71.80 | -3.91 | -5.17% | |
| CH:ALC | Alcon | 59.10 | 0.43 | 0.73% | |
| CH:TECN | Tecan Group AG | 247.00 | 108.93 | 78.89% | |
| CH:PPGN | PolyPeptide Group AG | 42.00 | 16.90 | 67.33% | |
| CH:SDZ | Sandoz Group Ltd | 82.38 | 27.68 | 50.62% | |
| CH:GALD | Galderma Group AG | 192.85 | 41.68 | 27.57% |
Siegfried Holding AG Corporate Events
Siegfried posts higher H1 profits, strengthens U.S. footprint with key acquisition
Siegfried reported higher first-half 2026 results, with net sales up 4.8% in local currencies to CHF 633 million and core EBITDA rising to CHF 142 million, lifting the margin to 22.4% on the back of sustained demand for both drug substances and drug...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 21, 2026